ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves New Imaging Study In Split Vote, Small Grant Program

October 27, 1989

Joseph Cullen, Cancer Prevention Leader, Dead At 54

November 30, 1990

“Landmark” Fundings Reported n Interferon Genes, Ovarian And Pancreas Markers

April 17, 1981

In Brief: McDonnell Foundation Selects Five For Awards; James Benson Is Named Interim FDA Head

November 24, 1989

NIH Programs: Mouse Is next In Line For DNA Sequencing

October 29, 1999

Includes June issue of Business & Regulatory Report.

June 28, 2002